Third quarter results from AstraZeneca, Clovis Oncology and Tesaro suggest that while PARP inhibitors are making some strides on the market, the drug class has yet to become the commercial success Wall Street thought it would be not too long ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,